Summit Therapeutics Inc. (SMMT) Earnings History
Annual and quarterly earnings data from 2003 to 2025
Loading earnings history...
SMMT EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
SMMT Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | -257.0% | -11259.8% | -11185.9% |
| 2021 | 100.0% | -4764.3% | -4897.8% |
Download Data
Export SMMT earnings history in CSV or JSON format
Free sign-in required to download data
Summit Therapeutics Inc. (SMMT) Earnings Overview
As of May 8, 2026, Summit Therapeutics Inc. (SMMT) reported trailing twelve-month net income of -$1.21B, reflecting -364.5% year-over-year growth. The company earned $-1.56 per diluted share over the past four quarters.
Looking at the long-term picture, SMMT's historical earnings data spans multiple years. The company achieved its highest annual net income of $11M in fiscal 2018.
Summit Therapeutics Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including KYMR (-$315M net income, -794.4% margin), RVMD (-$1.37B net income), TNGX (-$102M net income, -162.9% margin), SMMT has comparable earnings metrics. Compare SMMT vs KYMR →
SMMT Earnings vs Peers
Earnings metrics vs comparable public companies
SMMT Historical Earnings Data (2003–2025)
23 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$1.08B | -387.8% | -$1.09B | $-1.44 | - | - |
| 2024 | -$221M | +64.0% | -$211M | $-0.31 | - | - |
| 2023 | -$615M | -680.5% | -$90M | $-0.99 | - | - |
| 2022 | -$79M | +11.1% | -$79M | $-0.41 | -11185.9% | -11259.8% |
| 2021 | -$89M | -68.1% | -$86M | $-0.96 | -4897.8% | -4764.3% |
| 2020 | -$53M | -120.6% | -$72M | $-0.76 | -6127.6% | -8330.9% |
| 2019 | -$24M | -319.7% | -$43M | $-0.73 | -3779.0% | -6766.4% |
| 2018 | $11M | +138.1% | $5M | $0.11 | 19.0% | 9.4% |
| 2017 | -$29M | -25.6% | -$26M | $-0.28 | -201.4% | -182.3% |
| 2016 | -$23M | +6.7% | -$31M | $-0.35 | -788.8% | -1078.6% |
Full SMMT Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See SMMT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SMMT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SMMT vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonSMMT — Frequently Asked Questions
Quick answers to the most common questions about buying SMMT stock.
Is SMMT growing earnings?
SMMT EPS fell to $-1.56, with earnings declining -364.5%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-1.2B.
What are SMMT's profit margins?
Summit Therapeutics Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are SMMT's earnings?
SMMT earnings data spans 2003-2025. The declining earnings trend is -364.5% YoY. Historical data enables comparison across business cycles.